PortalPublikationenContemporary vs historical survival rates in metastatic clea...

Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity

Standard

Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. / Sorce, Gabriele; Hoeh, Benedikt; Hohenhorst, Lukas; Panunzio, Andrea; Tappero, Stefano; Nimer, Nancy; Tian, Zhe; Larcher, Alessandro; Capitanio, Umberto; Tilki, Derya; Terrone, Carlo; Chun, Felix K H; Antonelli, Alessandro; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

in: WORLD J UROL, Jahrgang 40, Nr. 12, 12.2022, S. 2971-2978.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sorce, G, Hoeh, B, Hohenhorst, L, Panunzio, A, Tappero, S, Nimer, N, Tian, Z, Larcher, A, Capitanio, U, Tilki, D, Terrone, C, Chun, FKH, Antonelli, A, Saad, F, Shariat, SF, Montorsi, F, Briganti, A & Karakiewicz, PI 2022, 'Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity', WORLD J UROL, Jg. 40, Nr. 12, S. 2971-2978. https://doi.org/10.1007/s00345-022-04183-0

APA

Sorce, G., Hoeh, B., Hohenhorst, L., Panunzio, A., Tappero, S., Nimer, N., Tian, Z., Larcher, A., Capitanio, U., Tilki, D., Terrone, C., Chun, F. K. H., Antonelli, A., Saad, F., Shariat, S. F., Montorsi, F., Briganti, A., & Karakiewicz, P. I. (2022). Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. WORLD J UROL, 40(12), 2971-2978. https://doi.org/10.1007/s00345-022-04183-0

Vancouver

Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Nimer N et al. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. WORLD J UROL. 2022 Dez;40(12):2971-2978. https://doi.org/10.1007/s00345-022-04183-0

Bibtex

@article{2d500ce9bd684e28aeb46e0c37cbdba3,
title = "Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity",
abstract = "PURPOSE: Systemic therapies (ST) improved contemporary survival rates, relative to historical in clear cell metastatic renal carcinoma (ccmRCC) patients. The magnitude of this improvement is unknown according to race/ethnicity.METHODS: Within the SEER registry (2000-2017), ccmRCC patients were stratified according to race/ethnicity (Caucasian, Hispanic, African American, Asian) and historical (2000-2009) vs contemporary (2010-2017) years of diagnosis. Competing risks regression (CRR) with adjustment for other-cause mortality and Poisson smoothed cumulative incidence plots addressed cancer-specific mortality (CSM).RESULTS: Of 10,141 mRCC patients, 4316 (43%) vs 5825 (57%) were diagnosed in historical vs contemporary era. Of 4316 historical patients, 3203 (74%) vs 593 (14%) vs 293 (7%) vs 227 (5%) were Caucasian, Hispanic, African American and Asian. Of 5825 contemporary patients, 4124 (71%) vs 977 (17%) vs 362 (6%) vs 362 (6%) were Caucasian, Hispanic, African American and Asian. Between 2000 and 2017, ST rates ranged from 12 to 57% in Caucasians, 2 to 57% in Hispanics, 33 to 50% in African Americans, 17 to 70% in Asians and universally increased toward a plateau in 2010. In Caucasians, CSM decreased from 80 to 74% vs 79 to 74% in Hispanics vs 79 to 77% in African Americans, but not in Asians (67-73%). Nonetheless, these rates translated into independent predictor status of contemporary years of diagnosis in all race/ethnicity groups: CSM hazard ratios of 0.75, 0.75, 0.73 and 0.80 in, respectively, Caucasian, Hispanic, African American and Asian.CONCLUSIONS: In all race/ethnicity groups, contemporary ST rates increased and improved CSM rates have also been recorded.",
keywords = "Humans, Carcinoma, Renal Cell/pathology, Ethnicity, Survival Rate, SEER Program, Kidney Neoplasms/pathology",
author = "Gabriele Sorce and Benedikt Hoeh and Lukas Hohenhorst and Andrea Panunzio and Stefano Tappero and Nancy Nimer and Zhe Tian and Alessandro Larcher and Umberto Capitanio and Derya Tilki and Carlo Terrone and Chun, {Felix K H} and Alessandro Antonelli and Fred Saad and Shariat, {Shahrokh F} and Francesco Montorsi and Alberto Briganti and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2022",
month = dec,
doi = "10.1007/s00345-022-04183-0",
language = "English",
volume = "40",
pages = "2971--2978",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity

AU - Sorce, Gabriele

AU - Hoeh, Benedikt

AU - Hohenhorst, Lukas

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Nimer, Nancy

AU - Tian, Zhe

AU - Larcher, Alessandro

AU - Capitanio, Umberto

AU - Tilki, Derya

AU - Terrone, Carlo

AU - Chun, Felix K H

AU - Antonelli, Alessandro

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

N1 - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2022/12

Y1 - 2022/12

N2 - PURPOSE: Systemic therapies (ST) improved contemporary survival rates, relative to historical in clear cell metastatic renal carcinoma (ccmRCC) patients. The magnitude of this improvement is unknown according to race/ethnicity.METHODS: Within the SEER registry (2000-2017), ccmRCC patients were stratified according to race/ethnicity (Caucasian, Hispanic, African American, Asian) and historical (2000-2009) vs contemporary (2010-2017) years of diagnosis. Competing risks regression (CRR) with adjustment for other-cause mortality and Poisson smoothed cumulative incidence plots addressed cancer-specific mortality (CSM).RESULTS: Of 10,141 mRCC patients, 4316 (43%) vs 5825 (57%) were diagnosed in historical vs contemporary era. Of 4316 historical patients, 3203 (74%) vs 593 (14%) vs 293 (7%) vs 227 (5%) were Caucasian, Hispanic, African American and Asian. Of 5825 contemporary patients, 4124 (71%) vs 977 (17%) vs 362 (6%) vs 362 (6%) were Caucasian, Hispanic, African American and Asian. Between 2000 and 2017, ST rates ranged from 12 to 57% in Caucasians, 2 to 57% in Hispanics, 33 to 50% in African Americans, 17 to 70% in Asians and universally increased toward a plateau in 2010. In Caucasians, CSM decreased from 80 to 74% vs 79 to 74% in Hispanics vs 79 to 77% in African Americans, but not in Asians (67-73%). Nonetheless, these rates translated into independent predictor status of contemporary years of diagnosis in all race/ethnicity groups: CSM hazard ratios of 0.75, 0.75, 0.73 and 0.80 in, respectively, Caucasian, Hispanic, African American and Asian.CONCLUSIONS: In all race/ethnicity groups, contemporary ST rates increased and improved CSM rates have also been recorded.

AB - PURPOSE: Systemic therapies (ST) improved contemporary survival rates, relative to historical in clear cell metastatic renal carcinoma (ccmRCC) patients. The magnitude of this improvement is unknown according to race/ethnicity.METHODS: Within the SEER registry (2000-2017), ccmRCC patients were stratified according to race/ethnicity (Caucasian, Hispanic, African American, Asian) and historical (2000-2009) vs contemporary (2010-2017) years of diagnosis. Competing risks regression (CRR) with adjustment for other-cause mortality and Poisson smoothed cumulative incidence plots addressed cancer-specific mortality (CSM).RESULTS: Of 10,141 mRCC patients, 4316 (43%) vs 5825 (57%) were diagnosed in historical vs contemporary era. Of 4316 historical patients, 3203 (74%) vs 593 (14%) vs 293 (7%) vs 227 (5%) were Caucasian, Hispanic, African American and Asian. Of 5825 contemporary patients, 4124 (71%) vs 977 (17%) vs 362 (6%) vs 362 (6%) were Caucasian, Hispanic, African American and Asian. Between 2000 and 2017, ST rates ranged from 12 to 57% in Caucasians, 2 to 57% in Hispanics, 33 to 50% in African Americans, 17 to 70% in Asians and universally increased toward a plateau in 2010. In Caucasians, CSM decreased from 80 to 74% vs 79 to 74% in Hispanics vs 79 to 77% in African Americans, but not in Asians (67-73%). Nonetheless, these rates translated into independent predictor status of contemporary years of diagnosis in all race/ethnicity groups: CSM hazard ratios of 0.75, 0.75, 0.73 and 0.80 in, respectively, Caucasian, Hispanic, African American and Asian.CONCLUSIONS: In all race/ethnicity groups, contemporary ST rates increased and improved CSM rates have also been recorded.

KW - Humans

KW - Carcinoma, Renal Cell/pathology

KW - Ethnicity

KW - Survival Rate

KW - SEER Program

KW - Kidney Neoplasms/pathology

U2 - 10.1007/s00345-022-04183-0

DO - 10.1007/s00345-022-04183-0

M3 - SCORING: Journal article

C2 - 36222885

VL - 40

SP - 2971

EP - 2978

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 12

ER -